v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491

ClinicalTrials.gov ID: NCT03447990

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03447990. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-blind, Placebo-controlled, Two-Part, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure With Reduced Ejection Fraction

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.

Study identification

NCT ID: NCT03447990
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bristol-Myers Squibb; Industry
Enrollment: 52 participants

Conditions and interventions

Conditions

Interventions

MYK-491 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 6, 2018 (Actual)
Primary completion: Oct 24, 2019 (Actual)
Completion: Oct 24, 2019 (Actual)
Last update posted: Feb 2, 2023

2018 – 2019

United States locations

U.S. sites: 9
U.S. states: 9
U.S. cities: 9

Facility	City	State	ZIP	Site status
Jacksonville Center for Clinical Research	Jacksonville	Florida	32216	—
Prism Reseach	Saint Paul	Minnesota	55102	—
St. Louis Heart and Vascular Cardiology	St Louis	Missouri	63136	—
Newark Beth Israel Medical Center	Newark	New Jersey	07112	—
Duke University Medical Center	Durham	North Carolina	27710	—
Ohio State University Medical Center	Columbus	Ohio	43210	—
Oregon Health & Science University	Portland	Oregon	97239	—
University of Pennsylvania Heart and Vascular Center	Philadelphia	Pennsylvania	19104	—
Tennessee Center for Clinical Trials	Tullahoma	Tennessee	37388	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03447990, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 2, 2023 · Synced Nov 13, 2026